SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

UpScrolled founder denounces “Zionist money” at Web Summit, claims Big Tech enabled genocide in Gaza

Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race

Vietnam to produce Rafael Spike missiles locally in $250 million deal

Wiz finds major flaw in Moltbook, the vibe-coded social network for AI bots

Buzz

Most popular

Daily

Weekly

1

Why Apple paid billions for a company with no revenue

2

Valued at $800 million after less than two years, Vega eyes the path blazed by Wiz

3

Israeli startups raise over $1 billion in January, marking best opening month since 2022

4

Google-Wiz deal expected to be cleared by EU following meeting with regulators, report says

5

From secret satellites to civilian services: Israel’s space industry reinvents itself

Gamida Cell

5 stories about Gamida Cell

ג'וליאן אדמס מנכ"ל גמידה

Gamida Cell announces $75 million financing with Highbridge Capital Management

The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases

Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO

28.10.18|Lilach Baumer

The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share

נאסד"ק וול סטריט

Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million

18.10.18|Lilach Baumer

The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms

נאסד"ק וול סטריט

Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO

30.09.18|Dror Reich

The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution

המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer

The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor